Full text
Earnings transcript
Read the complete earnings call transcript.
ANGO
AngioDynamics, Inc.
$12.34
0.41
(3.44%)
| Exchange: | NASDAQ |
| Market Cap: | 509.875M |
| Shares Outstanding: | 9.2M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | James C. Clemmer | |||||
| Full Time Employees: | 748 | |||||
| Address: |
| |||||
| Website: | https://www.angiodynamics.com |
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company’s portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 338,752 | 303,914 | 292,498 |
| Gross Profit | 174,246 | 154,698 | 157,705 |
| EBITDA | 12,194 | -6,132 | 1,738 |
| Operating Income | -51,181 | -192,435 | -39,954 |
| Net Income | -52,442 | -184,349 | -33,993 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 532,637 | 317,671 | 280,144 |
| Total Liabilities | 154,341 | 112,085 | 97,174 |
| Total Stockholders Equity | 378,296 | 205,586 | 182,970 |
| Total Debt | 49,818 | 5,914 | 0 |
| Cash and Cash Equivalents | 44,620 | 76,056 | 55,893 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 78 | -28,158 | -10,808 |
| Capital Expenditure | -4,352 | -5,768 | -4,464 |
| Free Cash Flow | -4,274 | -33,926 | -15,272 |
| Net Income | -52,442 | -184,349 | -33,993 |
| Net Change in Cash | 15,795 | 31,436 | -20,163 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 387,379.008 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 395,401.898 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 391,639 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 5,914.867 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 6,037.368 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 5,979.913 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 11,717.325 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 12,033.722 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 11,885.360 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 172,142.638 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 175,707.832 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 174,035.684 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.290 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.290 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.290 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Growth: AngioDynamics reported a total revenue of $80.2 million in its Fiscal Year 2025 Q4 earnings, reflecting positive growth driven by its MedTech portfolio. This performance indicates a strong market position within the medical devices sector.
- Operational Efficiency: The company emphasized a focus on operational improvements during the Q4 2025 earnings call, which likely contributed to sustained gross profit margins (as inferred from revenue growth and strategic focus), enhancing profitability potential.
- Strong MedTech Portfolio: The earnings call highlighted the company’s innovative product offerings in the MedTech space as a key driver of growth, positioning ANGO favorably against competitors in the industry.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about ANGO valuation
Is AngioDynamics, Inc. (ANGO) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for AngioDynamics, Inc. (ANGO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ANGO a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ANGO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ANGO’s P/E ratio?
You can see ANGO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ANGO?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ANGO a good long-term investment?
Whether ANGO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ANGO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
3.44
Trading Metrics:
| Open: | 11.95 | Previous Close: | 11.93 | |
| Day Low: | 11.91 | Day High: | 12.38 | |
| Year Low: | 8.36 | Year High: | 13.99 | |
| Price Avg 50: | 11.02 | Price Avg 200: | 11.32 | |
| Volume: | 225954 | Average Volume: | 393009 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeANGO full analysis
Welcome to MARKETSNAP’s SWOT analysis for AngioDynamics, a company that might not be on everyone’s radar but definitely deserves a closer look if you’re hunting for potential in the healthcare space. I’m thrilled to dive into this one with you today because there’s a lot to unpack—some promising trends, a few red flags, and plenty of food for thought for long-term investors like us. So, let’s get right into it and break down what makes AngioDynamics tick, where it stands…
